Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells (Q42844418)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 28, 2010

Language	Label	Description	Also known as
English	Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells	scientific article published on October 28, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells (English)

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

1 reference

based on heuristic

inferred from title

6

object named as

Choung-Soo Kim

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

5

object named as

In Gab Jeong

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

author name string

Jung Jin Hwang

1

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Yong Sook Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Mi Joung Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Dong Eun Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

language of work or name

0 references

publication date

28 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0022534710042357?httpAccept=text/xml

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

https://api.elsevier.com/content/article/PII:S0022534710042357?httpAccept=text/plain

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

http://www.jurology.com/doi/pdf/10.1016/j.juro.2010.07.035

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

184

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

2557-2564

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Cancer statistics, 2009

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

2

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

3

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Docetaxel-based combination therapy for castration-resistant prostate cancer

4

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

5

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Rational development of histone deacetylase inhibitors as anticancer agents: a review

6

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

7

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Histone deacetylase inhibitors: molecular mechanisms of action

8

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

HDAC inhibitors: clinical update and mechanism-based potential.

9

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

10

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

The role of histone deacetylases in prostate cancer.

11

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

12

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

13

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

14

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

15

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells

16

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

17

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

18

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.

19

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

20

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Altered epigenetic signals in human disease.

23

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

24

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

25

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Targeting the androgen receptor pathway in prostate cancer

26

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Microtubules containing acetylated alpha-tubulin in mammalian cells in culture

27

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.

28

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells

29

1 reference

10.1016/J.JURO.2010.07.035

https://api.crossref.org/works/10.1016/J.JURO.2010.07.035

16 August 2024

Identifiers

10.1016/J.JURO.2010.07.035

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42844418&oldid=2228564999"